Home > Journals > Acta Vulnologica > Past Issues > Acta Vulnologica 2005 June;3(2) > Acta Vulnologica 2005 June;3(2):63-9

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

ACTA VULNOLOGICA

A Journal on Physiopathology and Therapy of Chronic Cutaneous Ulcers


Official Journal of the Italian Association for Cutaneous Ulcers
Indexed/Abstracted in: EMBASE, Scopus, Emerging Sources Citation Index


eTOC

 

ORIGINAL ARTICLES  


Acta Vulnologica 2005 June;3(2):63-9

language: Italian

Use of Urgotul S.ag in the local treatment of chronic infected ulcers: observational study

Crespi A. 1, Martinoli M. 2, Ferrari A. 3, Lombardi A. 4

1 Dipartimento di Chirurgia Generale ASL 13 Novara, Novara
2 Dipartimento di Chirurgia Generale ASL 13 Novara, Novara
3 Ambulatorio Lesioni Cutanee P.O. San Rocco - Galliate - ASL 13 Novara, Novara
4 Servizio Cure Domiciliari di Novara ASL 13 Novara, Novara


PDF  


Aim. The aim of the study was to use Urgotul S.Ag on vascular chronic cutaneous lesions of the lower extremities in the presence of bacterial contamination or colonisation, silver-sulphadiazine playing the role of powerful, broad spectrum local antiseptic.
Methods. Twelve patients were followed at the Clinic of Skin Lesions of the San Rocco Hospital of Galliate and at the Home Treatment Department of ASL 13 (District of Novara) for a total of 12 lesions, employing Urgotul S.Ag (version containing silver-sulphadiazine).
Results. A weekly clinical assessment was carried out until all signs of bacterial contamination and colonisation of the lesion had completely regressed.
Conclusion. Urgotul S.Ag protects the perilesional skin thanks to lipid particles that do not dissociate from the polyester reticulum that supports them, favour tissue granulation thanks to the presence of hydrocolloidal particles that create a humid, non-occlusive environment, reduce the bacterial load of the bed of the lesion below the colonisation threshold owing to the presence of an antiseptic like silver sulphadizine and make it possible to keep the medication in situ up to 48 hours since the S.Ag present in Urgotul is released to the lesion slowly and in controlled fashion.

top of page

Publication History

Cite this article as

Corresponding author e-mail